kabutan

Carna Biosciences, Inc.(4572) Summary

4572
TSE Growth
Carna Biosciences, Inc.
239
JPY
-1
(-0.42%)
Dec 5, 2:13 pm JST
1.54
USD
Dec 5, 12:13 am EST
Result
PTS
outside of trading hours
238
Dec 5, 2:07 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.29
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
240 JPY 1.54 USD
Previous Close Dec 4
240 JPY 1.54 USD
High Dec 5, 9:05 am
241 JPY 1.55 USD
Low Dec 5, 10:05 am
232 JPY 1.49 USD
Volume
345,900
Trading Value
0.08B JPY 0.53M USD
VWAP
238.38 JPY 1.54 USD
Minimum Trading Value
23,900 JPY 154 USD
Market Cap
4.58B JPY 0.03B USD
Number of Trades
244
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
194
1-Year High Aug 8, 2025
2,105
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 1,471,300
Nov 21, 2025 0 1,518,200
Nov 14, 2025 0 1,548,500
Nov 7, 2025 2,500 1,580,900 632.36
Oct 31, 2025 0 1,593,800
Company Profile
Carna Biosciences, Inc. specializes in drug discovery support services, primarily focusing on the production and sale of kinase proteins and analysis outsourcing. The company is also expanding into drug discovery.
Sector
Pharmaceuticals
Carna Biosciences, Inc. offers a diverse range of products and services supporting early-stage drug discovery, including the manufacture and sale of kinase proteins, assay development, profiling and screening services, and cell-based assay services. The company's strength lies in its extensive lineup of kinase proteins and assay kits. Additionally, Carna Biosciences is focusing on in-house drug discovery with kinase inhibitors, advancing research and development of new drugs in key disease areas such as cancer and immune-inflammatory disorders. For cancer-related projects, the company plans to conduct studies up to Phase II trials at most, while for other diseases, it aims to carry out Phase I trials or preclinical studies before out-licensing to pharmaceutical companies.